Prostate Cancer Scientific Abstracts - H

Welcome to the Prostate Cancer Guide scientific abstracts, author section H. Here you will find abstracts from the latest research being carried out in the field.

This section is recommended for people who have a scientific interest in prostate cancer. It is recommended that people without prior knowledge of prostate cancer visit the more general areas of the site (Prostate Cancer Guide).

Abstract Authors


Latest Prostate Cancer Abstract

Journal: Investigational New Drugs.

Issue: 2006, 24(4):311-9.

Pubmed ID: 16683074

Authors: Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, Macdonald JR, Misset JL, Cvitkovic E.

Title: A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Background: To determine maximum tolerated dose, recommended dose, safety and pharmacokinetics of irofulven combined with cisplatin in advanced solid tumor patients.

Patients and methods: Cisplatin and irofulven were given sequentially i.v. over 30 min on day 1 and 15 every 4 weeks. Four dose levels (DL) were explored: irofulven (mg/kg)/cisplatin (mg/m(2)): DL1: 0.3/30; DL2: 0.4/30; DL3: 0.4/40; DL4: 0.5/40. Dose-limiting toxicity included dosing omission and delay >1 week. Maximum tolerated dose was the DL with DLT in 2/2 or >/=2/6 patients during cycle 1-2.

Results: Between March 2002 and April 2003, 33 patients were treated. Dose-limiting toxicity occurred in 1/6 patients in DL1 (hypomagnesemia, hypocalcemia); 1/6 in DL2 (thrombocytopenia); 2 heavily pretreated patients out of 6 patients in DL3 (neutropenic infection, thrombocytopenia, stomatitis); 2/3 in DL4 (asthenia, blurred vision). Three dose-limiting toxicity occurred in 12 additional patients treated at DL2. No toxic deaths occurred; grade 4 toxicity and grade 3 non-hematological toxicity were infrequent. Six patients reported grade 1-2 visual events. Antitumor activity was observed over a broad spectrum of tumor types in all DLs: 1 partial response in bulky sarcoma (DL1); 1 clinical response in endometrial carcinoma (DL1); 2 partial responses not confirmed due to discontinuation (ovarian DL2, renal DL4); 8 stabilizations >3 months; PSA response: 3/9 prostate cancer patients. Irofulven showed rapid elimination and high interpatient variability. Platinum and irofulven pharmacokinetics did not suggest drug-drug interactions.

Conclusion: Irofulven with cisplatin was adequately tolerated and substantial evidence of antitumor activity was observed. The recommended dose is irofulven 0.4 mg/kg and cisplatin 30 mg/m(2).

Contact: Department of Urology, Field of Oncology, Course of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan.

© Prostate Cancer Guide inc. 2006 - 2015